SI9420001B - Polipeptidni antagonisti bombezina - Google Patents

Polipeptidni antagonisti bombezina Download PDF

Info

Publication number
SI9420001B
SI9420001B SI9420001A SI9420001A SI9420001B SI 9420001 B SI9420001 B SI 9420001B SI 9420001 A SI9420001 A SI 9420001A SI 9420001 A SI9420001 A SI 9420001A SI 9420001 B SI9420001 B SI 9420001B
Authority
SI
Slovenia
Prior art keywords
alkyl
phenyl
hydrogen
peptide
moiety
Prior art date
Application number
SI9420001A
Other languages
English (en)
Other versions
SI9420001A (en
Inventor
Andrew V. Schally
Zhi Cai Ren
Original Assignee
The Administrators Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of filed Critical The Administrators Of
Publication of SI9420001A publication Critical patent/SI9420001A/sl
Publication of SI9420001B publication Critical patent/SI9420001B/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086Bombesin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (14)

  1. PATENTNI ZAHTEVKI 1. Bombezinski antagonistični peptid s formulo: X-A1-Az-Trp-Ala-Val-Gly-His-Leu-psi-A9-Q kjer je X vodik, enojna vez, ki veže alfa amino skupino A1 na gama karboksilni delež na 3-propionilnem deležu A2, če je A2 Glu[-], ali skupina s formulo R'CO-, kjer R1 izberemo izmed skupin, ki j ih sestavljajo a) vodik, Cj 10-alkil, fenil, fenil-Cj ]0-alkil, p-HI-fentl, p-HI-fenil-Cj 10-alkil, naftil, naftil-Cj 10-alkil, indolil, indolil-Cj 10-alkil, piridil, piridil-Cj 10-alkil, tienil, tienil-Cj 10-alkil, cikloheksil ali cikloheksil-Cj 10-alkil, kjer je HI = F, Cl, Br, OH, CH3 ali OCH^ b) R2 R3 > N— kjer je R2 vodik, Cj 10-alkil, fenil ali fenil-Cj 10-alkil, R3 je vodik ali C1_10-alkil; c) R4-0, kjer je R4 Cj 10-alkil, fenil ali fenil-CM0-alkil; A1 je D- ali L-amino kislinski ostanek, izbran iz skupine, ki jo sestavljajo Phe, p-HI-Phe, pGlu, Nal, Pal, Tpi, nesubstituiran Trp ali Trp substituiran v benzenskem obroču z enim ali več členi, izbranimi iz skupine, ki jo sestavljajo F, Cl, Br, NH2 ali C13-alkil; ali peptidna vez, ki veže acilni delež R^O na alfa amino delež A2, pod pogojem, da je X = R^O; A2 je Gin, Glu [-], Glu (Y), ali His, kjer je [-] enojna vez, če je X enojna vez in je A2 Glu[-], pri čemer [-] veže gama 1 z karboksilni delež na 3-propionilnem deležu A2 z alfa amino skupino A1, Y je a) -OR5, kjer je R5 vodik, Cj 3-alkil ali fenil; ali b) R6 — N R7 kjer je R6 vodik ali Cj 3-alkil; R7 je vodik, 3-alkil ali -NHCONl·^ in je Leu-psi- reducirana oblika Leu, kjer je C = O delež namesto -CLtako da je vez tega -CRj- deleža z alfa amino deležem sosednjega A9 ostanka psevdopeptidna vez; A9 je Tac, MTac, ali DMTac; in Q je NH2 ali -OO1, kjer je O1 vodik, C]!0-alkil, fenil ali fenil-Cj 10-alkil; in njegove farmacevtsko sprejemljive kisline ali soli.
  2. 2. Peptid po zahtevku 1, označen s tem, da je X = vodik ali R^O, kjer je R = H ali C310-alkil; A1 je D-Cpa, D-Nal, L- ali D-Pal, D-Phe, L- ali D-Tpi, ali D-Trp; A2 je Gin ali His; in Q je NH^.
  3. 3. Peptid po zahtevku 2, označen s tem, da je A9 Tac.
  4. 4. Peptid po zahtevku 2, označen s tem, da je A9 DMTac.
  5. 5. Peptid po zahtevku 3, označen s tem, da je X vodik ali Ac, A1 je D-Phe, L- ali D-Tpi, in A2 je Gin.
  6. 6. Peptid po zahtevku 4, označen s tem, da je X vodik ali Ac, A1 je D-Phe, L- ali D-Tpi, in A2 je Gin. 3 3
  7. 7. Peptid po zahtevku 3 s formulo sekv.id.št.2 D-Phe-Gln-Trp-Ala-Val-Glv-His-Leu-psi-Tac-NH-.·
  8. 8. Peptid po zahtevku 3 s formulo sekv.id.št.13 D-Tpi-Gln-Trp-Ala-Val-Glv-His-Leu-psi-Tac-NI-L,·
  9. 9. Peptid po zahtevku 4 s formulo sekv.id.št.18 D-Phe-Gln-Trp-Ala-Val-Glv-His-Leu-psi-DMTac-NH^.
  10. 10. Bombezinskj antagonistični peptid s formulo: X-A1-A2-Trp-Ala-Val-Glv-His-Leu-psi-A9-Q kjer je X vodik, enojna vez, ki veže alfa amino skupino A1 na gama karboksilni delež na 3-propionilnem deležu A2, če je A2 = Glu[-]; ali skupina s formulo R^CO-, kjer R1 izberemo izmed skupin, ki jih sestavljajo a) vodik, CM0-alkil, fenil ali fenil-C, 10-alkil; b) R2
    N— kjer je R2 vodik, Cj 10-alkil, fenil ali fenil-CM0-alkil, R3 je vodik ali CM0-alkil; c) R4-0, kjer je R4 = CM0-alkil, fenil ali fenil-Cj 10-alkil; A1 je nenaravna amino kislina, izbrana iz skupine, ki jo sestavljajo L- ali D-Pal ali L-ali D-Tpi; A2 je Gin, Glu [-], Glu (Y) ali His, kjer je [-] enojna vez, če je X enojna vez in je A2 Glu[-], pri čemer [-] veže gama karboksilni delež na 3-propionilnem deležu A2 z alfa amino skupino A1, Yje a) -OR5, kjer je R5 vodik, Cj 3-alkil ali fenil; b) R6
    kjer je R6 vodik ali C5 3-alkil; R7 je vodik, Cj 3-alkil ali -NHCONl·^ in je Leu-psi- reducirana oblika Leu, kjer je C = O delež namesto -CH^-, tako da je vez tega -CH2- deleža z alfa amino skupino sosednjega A9 ostanka psevdopeptidna vez; A9 je Cys ali Pen; in Q je NH2 ali -OQ\ kjer je O1 vodik, CM0-alkil, fenil ali fenil-Cj 10-alkil; in njegove farmacevtsko sprejemljive kisline ali soli.
  11. 11. Bombezinski antagonistični peptid po zahtevku 1, označen s tem, da je XjeR1CO, A1 je peptidna vez, ki veže acilni delež RjCO- na alfa amino delež A2; A2 je Gin ali His; in Q je NHr
  12. 12. Peptid po zahtevku 11, označen s tem, da je X = Hca, Hna, Paa, Mpp, Hpp ali Naa, A2 je Gin in A9 je Tac.
  13. 13. Peptid po zahtevku 12 s formulo sekv.id.št.14 Hca-Gln-Trp-Ala-Val-Gly-His-Leu-psi-Tac-NH2.
  14. 14. Farmacevtski sestavek, označen s tem, da vsebuje polipeptid po zahtevku 1, njegovo terapevtsko sprejemljivo obliko adicijske soli ali kompleks le-teh in njihov farmacevtsko sprejemljiv tekoč ali trden nosilec.
SI9420001A 1993-03-15 1994-03-07 Polipeptidni antagonisti bombezina SI9420001B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/031,325 US5369094A (en) 1990-11-29 1993-03-15 Polypeptide bombesin antagonists
PCT/US1994/002511 WO1994021674A1 (en) 1993-03-15 1994-03-07 Polypeptide bombesin antagonists

Publications (2)

Publication Number Publication Date
SI9420001A SI9420001A (en) 1995-08-31
SI9420001B true SI9420001B (sl) 1999-08-31

Family

ID=21858823

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9420001A SI9420001B (sl) 1993-03-15 1994-03-07 Polipeptidni antagonisti bombezina

Country Status (27)

Country Link
US (1) US5369094A (sl)
EP (1) EP0646127B1 (sl)
JP (1) JP3838656B2 (sl)
KR (1) KR100306506B1 (sl)
AT (1) ATE167874T1 (sl)
AU (1) AU666270B2 (sl)
BR (1) BR9404341A (sl)
CA (1) CA2135787C (sl)
CZ (1) CZ286750B6 (sl)
DE (1) DE69411342T2 (sl)
DK (1) DK0646127T3 (sl)
EE (1) EE03180B1 (sl)
ES (1) ES2120615T3 (sl)
FI (1) FI945378A (sl)
HR (1) HRP940164B1 (sl)
HU (1) HU218288B (sl)
IL (2) IL108851A (sl)
NO (1) NO313418B1 (sl)
NZ (2) NZ299913A (sl)
PL (1) PL180372B1 (sl)
RU (1) RU2114118C1 (sl)
SI (1) SI9420001B (sl)
SK (1) SK282267B6 (sl)
TW (1) TW325478B (sl)
UA (1) UA34456C2 (sl)
WO (1) WO1994021674A1 (sl)
ZA (1) ZA941767B (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US5877277A (en) 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US5650395A (en) * 1995-03-13 1997-07-22 Hurel; Steven Treatment of pulmonary hypertension
US6989371B1 (en) 1996-08-16 2006-01-24 Dabur Research Foundation Bombesin analogs for treatment of cancer
US6200546B1 (en) 1997-04-22 2001-03-13 The Curators Of The University Of Missouri Gastrin receptor-avid peptide conjugates
CA2426521A1 (en) * 2000-11-17 2002-05-23 Warner-Lambert Company Llc Treatment of sexual dysfunction using bombesin antagonist
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7850947B2 (en) 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US20060239923A1 (en) * 2003-01-13 2006-10-26 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US8420050B2 (en) * 2003-01-13 2013-04-16 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7922998B2 (en) * 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
ATE435035T1 (de) * 2003-01-13 2009-07-15 Bracco Imaging Spa Verbesserte linker für radiopharmazeutische verbindungen
US7611692B2 (en) * 2003-01-13 2009-11-03 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
JP4578470B2 (ja) 2003-04-22 2010-11-10 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ソマトスタチンベクター
US7795385B2 (en) * 2004-12-17 2010-09-14 Bexar Global, Inc. Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
EP2100900A1 (en) * 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
EP2198878A1 (en) * 2008-12-18 2010-06-23 University Of Miami Polypeptide bombesin antagonists
US8829196B2 (en) 2009-10-07 2014-09-09 Merck Sharp & Dohme Corp. TRPA1 antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162497A (en) * 1987-09-24 1992-11-10 The Administrators Of The Tulane Educational Fund Bradykinin analogs with non-peptide bond
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
JP2795449B2 (ja) * 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
AU618029B2 (en) * 1987-11-02 1991-12-12 Imperial Chemical Industries Plc Polypeptide compounds
GB8813356D0 (en) * 1988-06-06 1988-07-13 Ici Plc Polypeptide compounds
GR1000608B (el) * 1988-07-21 1992-08-31 Erba Carlo Spa Μεθοδος για την παρασκευη ανταγωνιστων bombesin.
MC2144A1 (fr) * 1988-10-14 1992-02-19 Univ Tulane Peptides therapeutiques
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists

Also Published As

Publication number Publication date
FI945378A0 (fi) 1994-11-15
NO944293L (no) 1995-01-02
ES2120615T3 (es) 1998-11-01
HU218288B (en) 2000-07-28
HRP940164B1 (en) 2000-02-29
RU2114118C1 (ru) 1998-06-27
SK136494A3 (en) 1995-08-09
PL180372B1 (pl) 2001-01-31
FI945378A (fi) 1994-11-15
KR950701646A (ko) 1995-04-28
ATE167874T1 (de) 1998-07-15
CZ280794A3 (en) 1995-07-12
EE03180B1 (et) 1999-04-15
PL306209A1 (en) 1995-03-06
IL108851A (en) 2003-05-29
NO944293D0 (no) 1994-11-10
BR9404341A (pt) 1999-08-31
DK0646127T3 (da) 1999-04-12
HUT69727A (en) 1995-09-28
EP0646127A1 (en) 1995-04-05
JPH07507330A (ja) 1995-08-10
WO1994021674A1 (en) 1994-09-29
SK282267B6 (sk) 2001-12-03
CZ286750B6 (en) 2000-06-14
HRP940164A2 (en) 1996-08-31
NO313418B1 (no) 2002-09-30
DE69411342T2 (de) 1998-11-19
TW325478B (en) 1998-01-21
UA34456C2 (uk) 2001-03-15
AU666270B2 (en) 1996-02-01
JP3838656B2 (ja) 2006-10-25
RU94046091A (ru) 1996-09-27
US5369094A (en) 1994-11-29
AU6444694A (en) 1994-10-11
EP0646127B1 (en) 1998-07-01
IL154995A0 (en) 2003-10-31
DE69411342D1 (de) 1998-08-06
KR100306506B1 (ko) 2001-12-01
SI9420001A (en) 1995-08-31
NZ299913A (en) 2000-07-28
CA2135787C (en) 2008-08-12
CA2135787A1 (en) 1994-09-29
NZ263668A (en) 1997-06-24
IL108851A0 (en) 1994-06-24
ZA941767B (en) 1994-10-06

Similar Documents

Publication Publication Date Title
SI9420001B (sl) Polipeptidni antagonisti bombezina
CA2272990A1 (en) Heptapeptide oxytocin analogues
CA2097192A1 (en) Bombesin antagonists
CA1244009A (en) Lh-rh antagonists
GB1533077A (en) 4-substituted enkephalin derivatives
GB1526367A (en) Polypeptide
ES2017028A6 (es) Procedimiento para preparar antagonistas de bombesina.
PT78209B (en) Gnrh antagonists iii
DE2158123A1 (de) Neue pharmazeutische Präparate
DE3267380D1 (en) Peptides and pseudopeptides in which the n terminus bears two substituents
KR920701242A (ko) 환원된 비가역성 봄베신 길항제
ES416516A1 (es) Un procedimiento para la preparacion de nonapeptidos.
GB1357121A (en) Peptide enzyme inhibitors
ES248724A1 (es) Procedimiento para la obtenciën de nuevosdecapeptures ciclicos
GB1430522A (en) N-substituted aspartyl peptide amides
GB1273873A (en) Corticotropically highly active octadecapeptides
Lübke et al. The Influence of Substitution or Omission of an Amino Group on the Hypotensive Activity of the C-Terminal Sequences of Eledoisin
FR4219M (sl)
GB1037143A (en) Polypeptides
GB1532148A (en) 1-substituted enkepholin derivatives
HRP921277A2 (en) Nonapeptide bombestin antagonists
TH17064B (th) ตัวปฏิปักษ์ต่อโปลีเปปไทด์บอมเบซิน

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20081112